| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |